Neisseria gonorrhoeae Ciprofloxacin Susceptibility Testing, PlexPrime GC+gyrA(550)
The PlexPrime GC+gyrA(550) kit is a single-well, multiplex assay designed for simultaneous detection of the following targets: opa and porA genes (N. gonorrhoeae-specific markers), gyrA S91F mutation (associated with ciprofloxacin resistance), gyrA S91 wild-type (associated with ciprofloxacin susceptibility) to detect N. gonorrhoeae resistance to ciprofloxacin in persistent or recurrent infections.
Neisseria gonorrhoeae (GC) is the etiological agent of Gonorrhea, which is one of the most common sexually transmitted infections (STIs) globally, with increasing antimicrobial resistance posing a significant public health challenge. Early detection and susceptibility testing are essential for effective treatment and infection control. Antimicrobial resistant GC is a global public health concern, and standard management using empiric treatment is being challenged by the spread of resistance and limited alternate treatment options. Individualized treatment guided by antibiotic susceptibility information has been proposed as a strategy to re-instigate the use of antibiotics no longer recommended for empiric treatment, while also conserving last-line therapies.
Ciprofloxacin, a fluoroquinolone antibiotic, is an excellent option for individualized treatment. While it was abandoned from empirical use in most regions from the 2000’s , large proportions of gonorrhoeae cases remain susceptible. In addition, the gyrA S91 wild type and gyrA S91F mutation markers are highly predictive of ciprofloxacin susceptibility and resistance, respectively. Molecular detection of the gyrA S91 wild type and gyrA S91F mutation markers may be used to guide effective ciprofloxacin treatment in patients with susceptible infections.
- Detection of N. gonorroeae strains resistance to ciprofloxacin in persistent infections
- Optimization of treatment plans based on susceptibility results
- Reduction in unnecessary use of last-line antibiotics
N. gonorrhoeae not detected (Negative) N. gonorrhoeae detected, gyrA mutation not detected
Vaginal swab, Urine, Liquid Cytology (ThinPrep, SurePath).
Stability
Vaginal Swab (Aptima Swab, UTM, M4 and other method specific transport media)
- Ambient: 2-3 days
- Refrigerated: 7 days
- Frozen: >1 month
Liquid Cytology (ThinPrep, SurePath)
- Ambient: 1 month
- Frozen: up to 1 year
- Lancet Microbe. 2023 Aug;4(8):e574. [PMID: 37236216]
- MLO Med Lab Obs. 2016 Dec;48(12):30. [PMID: 30047666]
- Lancet Microbe. 2023 Jul;4(7):e544-e551. [PMID: 37336225]
- Sex Transm Dis. 2017 May;44(5):261-265. [PMID: 28407640]
- PLoS One. 2022 Mar 10;17(3):e0264149. [PMID: 35271599]
- J Antimicrob Chemother. 2022 Oct 28;77(11):2933-2936. [PMID: 35880750]